Adding Yervoy to Opdivo Increases Responses in Some Ovarian Cancer Patients, Phase 2 Study Shows

Adding Yervoy to Opdivo Increases Responses in Some Ovarian Cancer Patients, Phase 2 Study Shows
A combination of Opdivo (nivolumab) and Yervoy (ipilimumab) leads to better response rates in patients with persistent or recurrent ovarian cancer than Opdivo alone, a Phase 2 study shows. The trial, sponsored by the National Cancer Institute, also showed that the combination significantly extends the time to disease progression or death. A trend toward better

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *